Therapeutic Response

MET Exon 14 (Deletion) status confers therapeutic sensitivity to Capmatinib in patients with Non-Small Cell Lung Cancer.

Statements

Source and description
Tabrecta (capmatinib) [product information]. EMA. The European Medicines Agency (EMA) has authorized capmatinib for the treatment of adult patients with advanced non-small cell lung cancer (NSCLC) with alterations leading to mesenchymal-epithelial transition factor gene exon 14 (MET exon 14) skipping, who require systemic therapy following prior treatment with immunotherapy and/or platinum-based chemotherapy.
Tabrecta (capmatinib) [package insert]. FDA. The U.S. Food and Drug Administration granted approval to capmatinib for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have a mutation that leads to mesenchymal-epithelial transition (MET) exon 14 skipping, as detected by an FDA-approved test.